BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32243728)

  • 21. Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy.
    Bianchi R; Cozzi G; Petralia G; Alessi S; Renne G; Bottero D; Brescia A; Cioffi A; Cordima G; Ferro M; Matei DV; Mazzoleni F; Musi G; Mistretta FA; Serino A; Tringali VML; Coman I; De Cobelli O
    Medicine (Baltimore); 2016 Oct; 95(40):e4519. PubMed ID: 27749525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiparametric MRI with in-bore targeted biopsy in the diagnostic pathway of prostate cancer: Data from a single institution experience.
    Nawfal G; Sarkis J; Assaf S; Mjaess G; Abi Chebel J; Semaan A; Alkassis M; Nemr E; Kamel G; Ayoub N; Sarkis P
    Urol Oncol; 2021 Nov; 39(11):781.e9-781.e15. PubMed ID: 33676850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ruling out clinically significant prostate cancer with negative multi-parametric MRI.
    An JY; Sidana A; Holzman SA; Baiocco JA; Mehralivand S; Choyke PL; Wood BJ; Turkbey B; Pinto PA
    Int Urol Nephrol; 2018 Jan; 50(1):7-12. PubMed ID: 29143253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gleason Score within Prostate Abnormal Areas Defined by Multiparametric Magnetic Resonance Imaging Did Not Vary According to the PIRADS Score.
    Slaoui H; Neuzillet Y; Ghoneim T; Rouanne M; Abdou A; Lugagne-Delpon PM; Scherrer A; Radulescu C; Delancourt C; Molinié V; Lebret T
    Urol Int; 2017; 99(2):156-161. PubMed ID: 28391284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study.
    Lee MS; Moon MH; Kim YA; Sung CK; Woo H; Jeong H; Son H
    AJR Am J Roentgenol; 2018 Jul; 211(1):114-120. PubMed ID: 29702017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seminal vesicle invasion on multi-parametric magnetic resonance imaging: Correlation with histopathology.
    Grivas N; Hinnen K; de Jong J; Heemsbergen W; Moonen L; Witteveen T; van der Poel H; Heijmink S
    Eur J Radiol; 2018 Jan; 98():107-112. PubMed ID: 29279147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance imaging in prostate cancer detection and management: a systematic review.
    Monni F; Fontanella P; Grasso A; Wiklund P; Ou YC; Randazzo M; Rocco B; Montanari E; Bianchi G
    Minerva Urol Nefrol; 2017 Dec; 69(6):567-578. PubMed ID: 28488844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study.
    Kam J; Yuminaga Y; Krelle M; Gavin D; Koschel S; Aluwihare K; Sutherland T; Skinner S; Brennan J; Wong LM; Louie-Johnsun M
    BJU Int; 2019 Aug; 124(2):297-301. PubMed ID: 30714285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.
    Beksac AT; Cumarasamy S; Falagario U; Xu P; Takhar M; Alshalalfa M; Gupta A; Prasad S; Martini A; Thulasidass H; Rai R; Berger M; Hectors S; Jordan J; Davicioni E; Nair S; Haines K; Lewis S; Rastinehad A; Yadav K; Jayaratna I; Taouli B; Tewari A
    J Urol; 2018 Dec; 200(6):1241-1249. PubMed ID: 30563651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies.
    Wegelin O; Exterkate L; van der Leest M; Kummer JA; Vreuls W; de Bruin PC; Bosch JLHR; Barentsz JO; Somford DM; van Melick HHE
    Eur Urol; 2019 Apr; 75(4):582-590. PubMed ID: 30522912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
    Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
    Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multi-parametric magnetic resonance imaging monitoring patients in active surveillance for prostate cancer: a prospective cohort study.
    Elkjær MC; Andersen MH; Høyer S; Pedersen BG; Borre M
    Scand J Urol; 2018 Feb; 52(1):8-13. PubMed ID: 29212392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy.
    Gupta RT; Faridi KF; Singh AA; Passoni NM; Garcia-Reyes K; Madden JF; Polascik TJ
    Urol Oncol; 2014 Nov; 32(8):1292-9. PubMed ID: 24863013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the accuracy of multiparametric MRI to predict clinically significant prostate cancer in biopsy naïve men across racial/ethnic groups.
    Meza J; Babajide R; Saoud R; Sweis J; Abelleira J; Helenowski I; Jovanovic B; Eggener S; Miller FH; Horowitz JM; Casalino DD; Murphy AB
    BMC Urol; 2022 Jul; 22(1):107. PubMed ID: 35850677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting DCE-MRI: Classification of Prostate Tissue Using Descriptive Signal Enhancement Features Derived From DCE-MRI Acquisition With High Spatiotemporal Resolution.
    Breit HC; Block TK; Winkel DJ; Gehweiler JE; Glessgen CG; Seifert H; Wetterauer C; Boll DT; Heye TJ
    Invest Radiol; 2021 Sep; 56(9):553-562. PubMed ID: 33660631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
    Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
    Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Which scores need a core? An evaluation of MR-targeted biopsy yield by PIRADS score across different biopsy indications.
    Sathianathen NJ; Konety BR; Soubra A; Metzger GJ; Spilseth B; Murugan P; Weight CJ; Ordonez MA; Warlick CA
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):573-578. PubMed ID: 30038389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting.
    Schlenker B; Apfelbeck M; Armbruster M; Chaloupka M; Stief CG; Clevert DA
    Clin Hemorheol Microcirc; 2019; 71(2):165-170. PubMed ID: 30562897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of PI-RADS v2 categories ≥ 3 for diagnosis of clinically significant prostate cancer.
    Patel NU; Lind KE; Garg K; Crawford D; Werahera PN; Pokharel SS
    Abdom Radiol (NY); 2019 Feb; 44(2):705-712. PubMed ID: 30171296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic accuracy of multiparametric magnetic resonance imaging in detecting extracapsular extension in intermediate and high - risk prostate cancer.
    Dominguez C; Plata M; Cataño JG; Palau M; Aguirre D; Narvaez J; Trujillo S; Gómez F; Trujillo CG; Caicedo JI; Medina C
    Int Braz J Urol; 2018; 44(4):688-696. PubMed ID: 29570254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.